Marker Therapeutics, Inc.

Monthly Archives: March 2016

TapImmune to Present at 28th Annual ROTH Conference on March 16, 2016

…TapImmune-Corporate-Presentation-2016

JACKSONVILLE, FLORIDA, March 14, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment of cancer, including metastatic cancer, announced today the company’s Director, Dr. John Bonfiglio will present at the 28th Annual ROTH Conference on March 16, 2016 at 11.30 AM PT in Salon 5.

Read More